Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A I Veldkamp

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Journal of Chromatography. B, Biomedical Sciences and Applications|February 17, 2000
Quantitative determination of abacavir (1592U89), a novel nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detectionA I Veldkamp, R W Sparidans, R M Hoetelmans, et al.
Therapeutic Drug Monitoring|May 22, 2001
Saliva as an alternative body fluid for therapeutic drug monitoring of the nonnucleoside reverse transcription inhibitor nevirapineR P van Heeswijk, A I Veldkamp, J W Mulder, et al.
AIDS (London, England)|July 14, 2000
Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot studyR P van Heeswijk, A I Veldkamp, J W Mulder, et al.
Therapeutic Drug Monitoring|January 22, 2002
Limited sampling strategies for the estimation of the systemic exposure to the HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapineA I Veldkamp, R P van Heeswijk, J W Mulder, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications|June 9, 1999
Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detectionA I Veldkamp, R P van Heeswijk, R M Hoetelmans, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications|November 26, 1999
Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detectionA I Veldkamp, R P van Heeswijk, P L Meenhorst, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|April 20, 2010
Limited stability of thiopurine metabolites in blood samples: relevant in research and clinical practiseP de Graaf, R M Vos, N H K de Boer, et al.
AIDS (London, England)|October 8, 1999
The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individualsR P van Heeswijk, A I Veldkamp, R M Hoetelmans, et al.
AIDS (London, England)|June 21, 2001
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individualsA I Veldkamp, G J Weverling, J M Lange, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 27, 2001
Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individualsA I Veldkamp, R P van Heeswijk, J W Mulder, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Journal of Chromatography. B, Biomedical Sciences and Applications|February 17, 2000
Quantitative determination of abacavir (1592U89), a novel nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detectionA I Veldkamp, R W Sparidans, R M Hoetelmans, et al.
Therapeutic Drug Monitoring|May 22, 2001
Saliva as an alternative body fluid for therapeutic drug monitoring of the nonnucleoside reverse transcription inhibitor nevirapineR P van Heeswijk, A I Veldkamp, J W Mulder, et al.
AIDS (London, England)|July 14, 2000
Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot studyR P van Heeswijk, A I Veldkamp, J W Mulder, et al.
Therapeutic Drug Monitoring|January 22, 2002
Limited sampling strategies for the estimation of the systemic exposure to the HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapineA I Veldkamp, R P van Heeswijk, J W Mulder, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications|June 9, 1999
Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detectionA I Veldkamp, R P van Heeswijk, R M Hoetelmans, et al.
Journal of Chromatography. B, Biomedical Sciences and Applications|November 26, 1999
Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detectionA I Veldkamp, R P van Heeswijk, P L Meenhorst, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|April 20, 2010
Limited stability of thiopurine metabolites in blood samples: relevant in research and clinical practiseP de Graaf, R M Vos, N H K de Boer, et al.
AIDS (London, England)|October 8, 1999
The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individualsR P van Heeswijk, A I Veldkamp, R M Hoetelmans, et al.
AIDS (London, England)|June 21, 2001
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individualsA I Veldkamp, G J Weverling, J M Lange, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 27, 2001
Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individualsA I Veldkamp, R P van Heeswijk, J W Mulder, et al.
Pageof 2